Skip to content
Kalpvruksh Markets
Offline Log in

AUROPHARMANSEOffline

AUROBINDO PHARMA · INE406A01037 · Mid Cap · #138
1,785.00+80.00 (+4.69%)last close · 05 Nov 2026
Prev close
1,705.00
Open
—
High
—
Low
—
Volume
—
Mkt cap (6-mo avg)
₹76,999 cr
52-week range · to 05 Nov 20261,121.71,785

Loading minute bars…

NSE 1-minute bars from our CandleApi gateway (history from 21 Jul 2026); longer timeframes are built from them. Prices not adjusted for corporate actions.

AUROPHARMA is at its 52-week high, above its 200-day average, ahead of Healthcare by 9.6 pts over 3 months — a Mid Cap company, #138 by market cap.NSE prices to 05 Nov 2026 · a description of the data, not advice

Overview

What the data says, line by line

A description, never a buy or sell word · tap a line for its detail

  • above its 20 / 50 / 200-day averages · at its 52-week high
  • ahead of its industry by 9.6 pts over 3 months · rank 15 of 44 in Healthcare · +13.1% vs Nifty 500
  • traded value 2.1× usual · delivery 53% vs 51% usual
  • short covering today · IV 24%, 12th pct of its year · expected move ±5.3% to expiry
  • FPI +1.0 pp · DII −0.7 pp · MF schemes in Sept 2026: 83 bought, 63 cut · promoter pledge 12.0% · quarter ended 2026-09-30
  • Jun 2026 quarter: profit +25% year on year · revenue +16%
  • nothing scheduled or restricting

How big is it?

six-month average market cap

Market capitalisation
₹76,999 cr
Rank
#138
Cap band
Mid Cap
Nearest cut-off — Large / Mid
−27.64% from ₹1,06,417 cr
Clear of the cut-off

Our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page.

Did buyers take delivery?

latest session · 2026-11-05

vs its own normal
3.9×
median 4,51,332
Delivered
17,73,473
Of volume
46%

Price & trend

Returns

to 05 Nov 2026

PeriodStockvs Nifty 500vs its industry
1 week+7.5%+1.6 pts—
1 month+5.4%+0.8 pts+1.5 pts
3 months+10.6%+13.1 pts+9.6 pts
6 months+20.3%+19.8 pts+8.5 pts
1 year+61.9%+66.2 pts—

Industry: Healthcare (Nifty 500 classification) · rank 15 of 44 over 3 months. Points = the stock’s return minus the benchmark’s. Prices adjusted for splits and bonuses.

Averages & movement

vs 20-day average
+7.6%
above
vs 50-day average
+6.8%
above
vs 200-day average
+21.6%
above
ATR (14)
3.0%
typical daily range
Volatility
29%
1 month, annualised
Beta
0.54
vs Nifty 500, 1 year
Traded value
2.1×
vs usual
Delivery
53%
usual 51%
From the 52-week high
0.0%
place in range 100% (0 = at the low)

F&O

Where option open interest clusters

expiry 23 Nov 2026 · 18 days

Spot
1,785.06
Max pain
1,700
−4.8% from spot
Largest call OI (strike)
Largest put OI (strike)

Near expiry. Max pain is the strike at which option buyers’ total payout would be least; strikes with the most open interest are where positions cluster.

Volatility & expected move

ATM IV
23.9%
near expiry
IV 30
23.8%
IV rank
18
0–100 within its year
IV percentile
12
days in the year below today
Expected move to expiry
±94.79
±5.3% · one standard deviation
Range
1,690 – 1,880
Rollover
1%
futures OI in next expiries

Futures build-up, by day

all expiries' OI · today: short covering

SessionBuild-upFuture priceOI, all expiries
05 Nov 2026short covering+4.1%−1.8%
04 Nov 2026long build-up+1.1%+2.6%
03 Nov 2026long build-up+0.7%+0.1%
02 Nov 2026long build-up+0.2%+0.9%
30 Oct 2026long build-up+1.3%+1.3%
29 Oct 2026long build-up+0.4%+0.1%
28 Oct 2026long build-up+1.3%+1.1%
27 Oct 2026long build-up+1.9%+0.3%
26 Oct 2026long build-up+1.7%+0.3%
23 Oct 2026long unwinding−2.4%−0.4%

From the exchanges’ F&O bhavcopies. A description of positions, not a forecast. Open interest across the market.

Ownership

Who owns the company

% of all shares, by quarter

GroupDec 25Mar 26Jun 26Sep 26
Promoters51.8%51.8%51.9% +0.151.9%
FPI13.9%15.2% +1.316.4% +1.117.4% +1.0
Mutual funds19.5%17.8% −1.716.7% −1.116.3% −0.4
Other DII8.1%8.0% −0.18.3% +0.38.1% −0.3
Individuals5.4%5.7% +0.45.4% −0.45.0% −0.3
Others1.2%1.4% +0.21.3% −0.11.3%

From the company’s quarterly shareholding pattern. Changes in percentage points against the quarter before. No quarters are on record between Sep 2022 and Jun 2025.

Promoter pledge

Sep 26

Of promoters’ holding
12.0%
Of all shares
6.2%
Jun 25 17.1%Sep 25 17.5%Dec 25 17.5%Mar 26 23.6%Jun 26 13.8%Sep 26 12.0%

Holders

Sep 26

All shareholders
2,33,737
Individuals
2,19,627

Indian passive funds’ stake

2026-06-30

Of free float
1.09%
Of all shares
0.53%
Schemes
93
Days to unwind
3.0
at 100% of volume

30,28,073 shares held by Indian passive mutual-fund schemes. A floor, not the total — foreign ETFs, insurance and EPFO are not counted.

Which funds bought and sold

mutual funds · quarter ended 2026-06-30

Funds holding
238
93 index · 145 active
Bought more
94
Sold some
110
4 closing out
FundSharesChangeDid
SBI Midcap Fund-Reg(G)Active+29,88,512+5977.0%bought
SBI ELSS Tax Saver Fund-Reg(IDCW)Active+14,31,180+2079.6%bought
SBI Multi Asset Allocation Fund-Reg(G)Active+4,68,711+1633.4%bought
Kotak Balanced Advantage Fund-Reg(G)Active−2,04,600−99.7%closing out
Invesco India Arbitrage Fund-Reg(G)Active−13,04,050−98.5%closing out
WOC Arbitrage Fund-Reg(G)Active−14,300−96.3%closing out

Ranked by how much each fund changed its own position, not by size of trade. Every fund here still holds the company — one that sold out entirely leaves no record to find.

Mutual-fund schemes, month by month

fund houses’ own monthly portfolios

MonthSchemesBought newAddedCutSold outShares heldValue
Sep 262201568585+0.7%₹14,480 cr
Aug 2621023883113−0.7%₹14,769 cr
Jul 261991158544−1.3%₹13,695 cr
Jun 2619211575510−3.7%₹13,864 cr
May 26191768749−1.7%₹13,013 cr
Apr 2619314734111−0.3%₹12,902 cr

Each month against the one before, counting only the fund houses that reported both (45 houses in Sep 26); a split or bonus is divided out first. “Partial” = fewer than five houses reported yet.

Fund ownership is a quarterly disclosure and counts Indian passive schemes only.

Results

Results

Events & filings

Insider trades

SEBI PIT disclosures filed with NSE

Promoter group
No market buy or sell
Directors & KMP
No market buy or sell
Others
No market buy or sell
Latest 7 of 35 disclosures
0 selected
30 Mar 2024RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding)Promoter GroupPledge Revoke1,16,35,862₹1,267 cr33.51%Revokation of Pledge
26 Mar 2024RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding)Promoter GroupPledge1,67,00,000₹1,759 cr33.51%Pledge Creation
23 Feb 2024RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding)Promoter GroupPledge Revoke23,00,000₹240 cr33.51%Revokation of Pledge
23 Feb 2024RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding)Promoter GroupPledge Revoke1,00,50,000₹1,049 cr33.51%Revokation of Pledge
14 Feb 2024RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding)Promoter GroupPledge1,34,00,000₹1,335 cr33.51%Pledge Creation
18 Jan 2024RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding)Promoter GroupPledge Revoke4,00,000₹44.99 cr33.51%Revokation of Pledge
16 Jan 2024RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding)Promoter GroupPledge2,50,000₹27.97 cr33.51%Pledge Creation

Sums count buys and sells of equity (market and off-market); pledges are listed but not summed. From NSE’s filings: the archive to 2 May 2026, its XBRL filings since (NSE circular NSE/CML/2026/12). A filing describes what was done, not why.

Disclosures & deals

last six months · NSE filings

  • Scheme / acquisition
    Aurobindo Pharma Limited has informed the Exchange about transfer ownership of Auro Pharma LLC, Russia, from Auro Active Pharma Private Limited to Auropharm Overseas Limited, wholly owned subsidiaries of the Company
    05 Nov 2026
  • Scheme / acquisition
    Acquisition (including agreement to acquire)-XBRL AUROBINDO PHARMA LIMITED has informed the Exchange regarding Acquisition (including agreement to acquire)
    05 Nov 2026
  • Board outcome
    Aurobindo Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
    05 Nov 2026
  • Board outcome
    Outcome of Board Meeting-XBRL AUROBINDO PHARMA LIMITED has informed the Exchange regarding Outcome of Board Meeting held on 04-Nov-2026 for Dividend
    05 Nov 2026
  • Scheme / acquisition
    Aurobindo Pharma Limited has informed the Exchange about Acquisition
    05 Oct 2026
  • Scheme / acquisition
    Acquisition (including agreement to acquire)-XBRL AUROBINDO PHARMA LIMITED has informed the Exchange regarding Acquisition (including agreement to acquire)
    05 Oct 2026

Latest shown; 8 in six months on all disclosures.

AUROPHARMA: only ratings, pledges, insider and takeover disclosures, buybacks, schemes, board outcomes and deals are listed. All deals.

Corporate actions

full published history

0 selected
EarlierDividend₹4Interim08 Aug 202508 Aug 2025
EarlierDividend₹1.5Interim20 Feb 202420 Feb 2024
EarlierDividend₹3Interim20 Nov 202320 Nov 2023
EarlierDividend₹3Interim17 Feb 202317 Feb 2023
EarlierDividend₹4.5Interim06 Jun 202207 Jun 2022
EarlierDividend₹1.5Interim18 Feb 202221 Feb 2022
EarlierDividend₹1.5Interim17 Nov 202118 Nov 2021
EarlierBonus1:1—20 Jul 201521 Jul 2015

8 shown. A falling price on an ex-date is not a loss: a dividend leaves the share as cash and a bonus multiplies the shares held.

Market capitalisation is our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page. Fund ownership is a quarterly disclosure and counts Indian passive schemes only. Nothing here is advice, a recommendation, or a view on the company.